Clinical trial Recruiting at 6 sites Observational

A no-biopsy method for diagnosing celiac disease using antibody tests

Official title: No-biopsy Approach for the Diagnosis of Celiac Disease: Definition of Cut-off Points for Different IgA Anti-tissue Transglutaminase Assays

Run by Instituto de Investigación Hospital Universitario La Paz · NCT05983978 · Data updated 2026-11-12

This study is testing a new way to diagnose celiac disease using blood tests instead of needing a biopsy, and it's for both kids and adults who are newly diagnosed.

Quick facts

Study typeObservational
SexAll
Enrollment150 (estimated)
SponsorInstituto de Investigación Hospital Universitario La Paz
Academic / other
Locations6 sites (Terrassa, Barcelona and 5 other locations)
StatusRecruiting
StartedJanuary 2, 2023
Main results expectedMarch 31, 2026
Study endsMarch 31, 2026
Registry record updatedAugust 6, 2025
Trial IDNCT05983978 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates include patients on a gluten-containing diet with elevated tTG-IgA antibodies and those meeting specific pediatric criteria without prior biopsy.

Probably not a fit

Patients already diagnosed with celiac disease or those who refuse a duodenal biopsy may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This multicenter observational study aims to establish optimal thresholds for IgA anti-tissue transglutaminase (tTG-IgA) antibody assays to diagnose celiac disease without requiring an intestinal biopsy. It will evaluate the diagnostic performance of various commercially available assays and determine if a titer cut-off above 10 times the upper limit of normal is effective across all tests. The study will enroll both pediatric and adult patients with new-onset celiac disease during 2023 and 2024, collecting serum samples for analysis. The research seeks to improve diagnostic accuracy and patient experience by minimizing invasive procedures.

Why it matters

Potential benefit: If successful, this approach could simplify and enhance the diagnosis of celiac disease, reducing the need for invasive biopsies.

How similar studies have gone: While similar approaches have been explored, this study aims to refine and validate specific cut-off points for various assays, making it a novel contribution to the field.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion criteria:

* Patients, on gluten-containing diet, with TGt-IgA antibodies \> Upper Limit of Normal (ULN) and intestinal biopsy confirming celiac disease (CD).
* Patients with TCRγδ+ \>10% combined with decrease NK-like intraepithelial lymphocytes in the intestinal epithelium.
* Paediatric patients who meet ESPGHAN criteria (TGt-IgA antibodies \>10xULN) without duodenal biopsy performed.

Exclusion criteria:

* Patients already diagnosed with CD.
* Patients who refused duodenal biopsy.
* Patients with primary or secondary immunodeficiencies.
* Patients with malignancy.
* Recruited patients whose remaining serum cannot be sent to the reference centre, whose biopsies are of poor quality or who nod not sign the informed consent from.

Where it's running

  • Hospital Mutua Terrassa
    Terrassa, Barcelona, Spain
    Recruiting
  • Hospital Universitario Lucus Augusti
    Lugo, Lugo, Spain
    Recruiting
  • Hospital Universitario La Paz
    Madrid, Madrid, Spain
    Recruiting
  • Hospital Sant Joan de Deu
    Barcelona, Spain
    Recruiting
  • Hospital Ramon y Cajal
    Madrid, Spain
    Recruiting
  • Hospital Universitario Fundación Jimenez Diaz
    Madrid, Spain
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.